The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis.

Autor: Butzkueven H; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.; The Alfred Hospital, Melbourne, VIC, Australia., Hillert J; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Soilu-Hänninen M; Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland., Ziemssen T; Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany., Kuhle J; Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.; Department of Neurology, University Hospital and University of Basel, Basel, Switzerland., Wergeland S; Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Medicine, University of Bergen, Bergen, Norway., Magyari M; Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Berger JR; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Moore N; Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France., Aydemir A; EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA., Bezemer I; Global Epidemiology, IQVIA, Amsterdam, The Netherlands., Sabidó M; Merck Healthcare KGaA, Darmstadt, Germany.

Publikováno v: Current medical research and opinion [Curr Med Res Opin] 2023 Oct; Vol. 39 (10), pp. 1367-1374. Date of Electronic Publication: 2023 Sep 07.

The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.

Autor: Butzkueven H; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.; The Alfred Hospital, Melbourne, Australia., Moore N; Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France., Aydemir A; Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA)., Sõnajalg J; Global Database Studies, IQVIA, Tartu, Estonia., Bezemer I; Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands., Korhonen P; IQVIA (former EPID Research), Espoo, Finland., Sabidó M; Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany.

Publikováno v: Current medical research and opinion [Curr Med Res Opin] 2022 Jul; Vol. 38 (7), pp. 1167-1176. Date of Electronic Publication: 2022 Apr 28.

Association of Azithromycin and Ventricular Arrhythmia: the ARITMO Project

Autor: Trifiro G, Oteri A, de Ridder M, Rijnbeek P, Pecchioli S, Mazzaglia G, Bezemer I, Garbe E, Schink T, Poluzzi E, Froslev T, Sturkenboom M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1299::f19a961134c7074e5f6ef4b033a25b60
http://hdl.handle.net/10281/225598

The Basic Principles of Pathophysiology of Venous Thrombosis.

Autor: Schulman, Sam^1,2 (AUTHOR) gemostasis@mail.ru, Makatsariya, Alexander² (AUTHOR) jamatotu@gmail.com, Khizroeva, Jamilya² (AUTHOR) vikabits@mail.ru, Bitsadze, Victoria² (AUTHOR), Kapanadze, Daredzhan³ (AUTHOR) daka.kapanadze@yandex.ru

Publikováno v: International Journal of Molecular Sciences. Nov2024, Vol. 25 Issue 21, p11447. 17p.

Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project.

Autor: Poluzzi, Elisabetta, Diemberger, I., De Ridder, M., Koci, A., Clo, M., Oteri, A., Pecchioli, S., Bezemer, I., Schink, T., Pilgaard Ulrichsen, S., Boriani, G., Sturkenboom, M., De Ponti, F., Trifirò, G.

Publikováno v: European Journal of Clinical Pharmacology; Nov2017, Vol. 73 Issue 11, p1499-1510, 12p